Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of tofacitinib on MRI-detected axial inflammation in psoriatic arthritis
2018-004254-22Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) and psoriatic spondylitis comparing Tofacitinib with Placebo (2 arms). Primary endpoint: Primary: Change in total Berlin MRI score (sacroiliac joints and spine) at 12 weeks. Started Jun 2019; status: terminated.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)psoriatic spondylitis
Beyond the preview
Go deeper on 2018-004254-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004254-22.